menu
    • menu
    [{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"}]

    Find Clinical Drug Pipeline Developments & Deals for Birinapant

    Menu

    Birinapant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medivir

                            Sweden arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : IGM Biosciences

                            Deal Size : $352.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

                            Details : IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells.

                            Product Name : TL32711

                            Product Type : Other Small Molecule

                            Upfront Cash : $1.0 million

                            November 01, 2021

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : IGM Biosciences

                            Deal Size : $352.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medivir

                            Sweden arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : IGM Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Birinapant Clinical Study Initiated By IGM Biosciences

                            Details : Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.

                            Product Name : TL32711

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2021

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : IGM Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Specialty & Agro Chemical
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Specialty & Agro Chemical
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Medivir Strengthens Its Business Development Possibilities Through a Renegotiated Agreement with Tetra Logic R...

                            Details : The original agreement between Medivir and TetraLogic included milestone payments with predetermined amounts as well as royalty obligations to TetraLogic if and when Medivir develops, markets or out-licenses birinapant further.

                            Product Name : TL32711

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 12, 2020

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth